CL2023001201A1 - Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados - Google Patents

Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados

Info

Publication number
CL2023001201A1
CL2023001201A1 CL2023001201A CL2023001201A CL2023001201A1 CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1 CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1
Authority
CL
Chile
Prior art keywords
treatment
hair loss
deuterated
regimens
loss disorders
Prior art date
Application number
CL2023001201A
Other languages
English (en)
Spanish (es)
Inventor
Cassella James
Original Assignee
Sun Pharmaceuticals Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceuticals Ind Inc filed Critical Sun Pharmaceuticals Ind Inc
Publication of CL2023001201A1 publication Critical patent/CL2023001201A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023001201A 2020-10-28 2023-04-26 Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados CL2023001201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02

Publications (1)

Publication Number Publication Date
CL2023001201A1 true CL2023001201A1 (es) 2023-11-17

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001201A CL2023001201A1 (es) 2020-10-28 2023-04-26 Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados

Country Status (14)

Country Link
US (1) US20230390292A1 (https=)
EP (1) EP4236956A1 (https=)
JP (1) JP2023553253A (https=)
KR (1) KR20230093504A (https=)
AU (1) AU2021372512A1 (https=)
CA (1) CA3196551A1 (https=)
CL (1) CL2023001201A1 (https=)
CO (1) CO2023006808A2 (https=)
DO (1) DOP2023000085A (https=)
IL (1) IL302401A (https=)
JO (1) JOP20230090A1 (https=)
MX (1) MX2023005027A (https=)
PE (1) PE20231945A1 (https=)
WO (1) WO2022094133A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3250876A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造jak抑制劑之方法及相關中間化合物
HRP20250965T1 (hr) 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
ES2988629T3 (es) * 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados
AU2020219797B2 (en) 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
CA3228505A1 (en) * 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
US20230390292A1 (en) 2023-12-07
JOP20230090A1 (ar) 2023-04-27
MX2023005027A (es) 2023-07-31
CA3196551A1 (en) 2022-05-05
IL302401A (en) 2023-06-01
PE20231945A1 (es) 2023-12-05
AU2021372512A1 (en) 2023-06-22
KR20230093504A (ko) 2023-06-27
JP2023553253A (ja) 2023-12-21
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
DOP2023000085A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
MX2018013347A (es) Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2021001951A1 (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
DOP2024000146A (es) Inhibidores de parp7
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
PE20241326A1 (es) Composiciones y tratamientos con nirogacestat
CL2022001102A1 (es) Métodos para el tratamiento de trastornos depresivos.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
AR131842A1 (es) Métodos para tratar gliomas
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
AR132852A1 (es) Combiterapia para tratar el cáncer
MX2023011686A (es) Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.
WO2025189114A8 (en) Cdk inhibitors and their use as pharmaceuticals
AR121415A1 (es) INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD
AR132470A1 (es) Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
DOP2025000167A (es) Inhibidores de prmt5–mta
CL2024003468A1 (es) Inhibidores de ripk1 y métodos de uso.